Welkom op de website van het Prinses Máxima Centrum.

Ga direct naar de inhoud of het hoofdmenu.

Den Boer Group

Monique den Boer

The Den Boer group focuses on the discovery of new (genetic) lesions and targets for precision medicines to improve the clinical outcome for children with acute lymphoblastic leukemia. We have expertise in so-called pathobiological studies addressing which (combination of) genetic lesions characterize the patients’ leukemia, how these lesions functionally contribute to therapy resistance and how these lesions affect the interaction of leukemic cells with the bone marrow microenvironment. This information is essential to develop strategies that kill leukemic cells more specifically.

Key Publications

Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, Den Boer ML. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. (2018) Leukemia, 32:931-940. PubMed PMID: 28972594

Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, van de Ven C, Koudijs MJ, Besselink NJM, de Groot-Kruseman HA, Zwaan CM, Horstmann MA, Pieters R, den Boer ML. JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia. (2017) Oncotarget 8:89923-89938. PubMed PMID: 29163799

Polak R*, de Rooij B*, Pieters R, Den Boer ML. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. (2015) Blood 126:2404-2414. PubMed PMID: 26297738 *shared first authorship

Van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, Van der Velden VHJ, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP*, Den Boer ML*. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. (2013) Blood 122: 2622-2629. PubMed PMID: 23974192 *shared last authorship

Den Boer ML, Van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters TCJM, Van Zutven LJCM, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. (2009) Lancet Oncol 10:125-134. PubMed PMID: 19138562

PI: Monique den Boer

Share this page on social media